As T1D can be effectively controlled with insulin, clinical development of any novel treatments, including disease-modifying therapies, has to include a broad assessment of safety parameters to meet very stringent criteria before the treatment can enter clinical practice [34, 35]. This evidence concerns the gene INS and type 1 diabetes mellitus.